What is TCRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TCRX?

P/E (TTM) is n/a and 52-week range is $0.22 to $2.57 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TCRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TCRX?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-5.92B, EPS (TTM) near $-0.91 when available from the market-data feed. Figures are informational and may lag live markets.

Where is TScan Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 65.3M shares outstanding, ISIN US89854M1018 when available from company profile and filing metadata.

TScan Therapeutics Inc

$TCRX

Health Care · Biotechnology

IR Run Scenarios

$0.24

+4.29%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 142 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.

Employees

142

Website

www.tscan.com

IPO

2021-07-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)